Find Clinical Trial

Home » Find Clinical Trials » An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic COlorectal cancer who are non-eligible for intensive therapy – TASCO1 study

An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic COlorectal cancer who are non-eligible for intensive therapy – TASCO1 study

← Back

Study Phase	Phase 2

Therapeutic Area	Cancers

Indication	Solid tumors

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	TIPIRACIL, TRIFLURIDINE, S095005

Active Substance Code	S095005

Protocol Code	CL2-95005-002

EudraCT Code	2015-004544-18

NCT Code	NCT02743221

Documents and links

First lay summary

Second lay summary

First results summary	READ MORE

Second results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.